Research Article
Noncoding RNA Transcripts during Differentiation of Induced Pluripotent Stem Cells into Hepatocytes
Table 1
Gene ontology categories of differentially expressed miRNA targets (pathway union).
| Comparison | KEGG pathway | value | #genes | #miRNAs |
| Upregulated miRNAs in HLC d24 compared to HLC d20 | Fatty acid biosynthesis | 0 | 1 | 2 | ECM-receptor interaction | 0 | 10 | 4 | Fatty acid metabolism | 5.984709e – 10 | 2 | 2 | Proteoglycans in cancer | 2.928118e − 09 | 31 | 3 | Hippo signaling pathway | 0.0001180971 | 13 | 3 | Steroid biosynthesis | 0.004048092 | 2 | 2 | Adherens junction | 0.01782237 | 11 | 2 | Base excision repair | 0.02708153 | 4 | 2 |
| Upregulated miRNAs in HLC d20 compared to HLC d24 | Lysine degradation | 1.389225e − 08 | 9 | 2 | Chronic myeloid leukemia | 0.0001602018 | 13 | 2 | Proteoglycans in cancer | 0.0002270705 | 12 | 1 | Wnt signaling pathway | 0.0006146658 | 12 | 1 | FoxO signaling pathway | 0.003220974 | 18 | 2 | Cell cycle | 0.003295535 | 9 | 1 | Pathways in cancer | 0.004235095 | 17 | 1 | Progesterone-mediated oocyte maturation | 0.03364343 | 8 | 1 | Oocyte meiosis | 0.03398087 | 5 | 1 | Signaling pathways regulating pluripotency of stem cells | 0.05899564 | 9 | 1 |
| Upregulated miRNAs in HLC d20 compared to hepatocytes | Fatty acid biosynthesis | 0 | 4 | 4 | ECM-receptor interaction | 0 | 29 | 10 | Lysine degradation | 0 | 26 | 17 | Proteoglycans in cancer | 0 | 115 | 18 | MicroRNAs in cancer | 2.065015e − 14 | 55 | 3 | Adherens junction | 1.92849e − 10 | 56 | 14 | Fatty acid metabolism | 2.435736e − 07 | 12 | 5 | Hippo signaling pathway | 2.854731e − 07 | 76 | 15 | Prion diseases | 3.567319e − 07 | 2 | 1 | Viral carcinogenesis | 4.563306e − 07 | 90 | 10 | Pathways in cancer | 7.078609e − 05 | 155 | 11 | Cell cycle | 0.0002485214 | 62 | 9 | p53 signaling pathway | 0.02762094 | 42 | 10 | Transcriptional misregulation in cancer | 0.02815897 | 70 | 8 |
| Upregulated miRNAs in hepatocytes compared to HLC d20 | Fatty acid biosynthesis | 0 | 4 | 7 | ECM-receptor interaction | 0 | 39 | 15 | Lysine degradation | 0 | 26 | 17 | Cell cycle | 0 | 92 | 17 | Viral carcinogenesis | 0 | 129 | 19 | Hippo signaling pathway | 0 | 92 | 23 | Proteoglycans in cancer | 0 | 140 | 23 | Pathways in cancer | 1.110223e − 16 | 235 | 20 | Adherens junction | 8.881784e – 16 | 59 | 20 | Hepatitis B | 3.774758e − 15 | 83 | 13 | Chronic myeloid leukemia | 3.940404e − 12 | 54 | 18 | Colorectal cancer | 3.432521e − 11 | 43 | 17 | Glioma | 9.944934e – 11 | 43 | 15 | Fatty acid metabolism | 1.771966e – 06 | 14 | 8 | p53 signaling pathway | 2.456315e – 06 | 47 | 16 | Small cell lung cancer | 8.452771e – 06 | 57 | 14 | Oocyte meiosis | 1.56543e − 05 | 65 | 12 | Thyroid hormone signaling pathway | 2.996244e – 05 | 64 | 11 | Steroid biosynthesis | 8.629469e – 05 | 7 | 12 | Prostate cancer | 0.0004910115 | 65 | 13 | PI3K-Akt signaling pathway | 0.001506451 | 118 | 10 | Focal adhesion | 0.001709285 | 81 | 9 | TGF-beta signaling pathway | 0.004683835 | 48 | 9 |
| Upregulated miRNAs in HLC d24 compared to hepatocytes | Prion diseases | 0 | 2 | 2 | Fatty acid biosynthesis | 0 | 4 | 6 | Fatty acid metabolism | 0 | 14 | 9 | Proteoglycans in cancer | 0 | 107 | 15 | ECM-receptor interaction | 0 | 34 | 18 | Adherens junction | 2.136489e – 10 | 52 | 16 | Viral carcinogenesis | 2.367215e – 07 | 84 | 11 | Hippo signaling pathway | 8.686167e – 05 | 76 | 14 | Pathways in cancer | 0.001098215 | 135 | 8 | Lysine degradation | 0.001337938 | 24 | 10 | Transcriptional misregulation in cancer | 0.003591186 | 53 | 7 | p53 signaling pathway | 0.04591601 | 39 | 11 |
| Upregulated miRNA hepatocytes compared to HLC d24 | Fatty acid biosynthesis | 0 | 4 | 7 | Hepatitis B | 0 | 91 | 15 | ECM-receptor interaction | 0 | 41 | 16 | Lysine degradation | 0 | 27 | 18 | Cell cycle | 0 | 93 | 18 | Viral carcinogenesis | 0 | 132 | 18 | Pathways in cancer | 0 | 247 | 21 | Hippo signaling pathway | 0 | 91 | 22 | Proteoglycans in cancer | 0 | 143 | 23 | Adherens junction | 5.662137e – 15 | 58 | 19 | Chronic myeloid leukemia | 1.465494e – 14 | 58 | 19 | Glioma | 8.104628e – 14 | 46 | 16 | Colorectal cancer | 8.277157e – 12 | 45 | 18 | p53 signaling pathway | 2.698853e – 08 | 47 | 17 | Oocyte meiosis | 1.888721e – 07 | 67 | 13 | Small cell lung cancer | 5.78931e − 07 | 61 | 15 | Thyroid hormone signaling pathway | 1.055741e – 05 | 64 | 11 | Prion diseases | 2.777397e – 05 | 6 | 2 | Steroid biosynthesis | 4.649816e – 05 | 10 | 11 | TGF-beta signaling pathway | 6.111763e – 05 | 52 | 11 | Prostate cancer | 0.0001105553 | 66 | 13 | Fatty acid metabolism | 0.0001381028 | 13 | 7 | PI3K-Akt signaling pathway | 0.0001991286 | 138 | 11 | FoxO signaling pathway | 0.001107838 | 84 | 15 | Focal adhesion | 0.001779401 | 90 | 9 | Bladder cancer | 0.002833066 | 27 | 12 | Melanoma | 0.01182136 | 41 | 10 | Protein processing in endoplasmic reticulum | 0.01436954 | 105 | 12 | Endocytosis | 0.01445943 | 97 | 12 |
|
|